# Xanamem™ in Healthy Elderly Subjects

> **NCT03830762** · PHASE1 · COMPLETED · sponsor: **Actinogen Medical** · enrollment: 42 (actual)

## Conditions studied

- Safety
- Peripheral Neuropathy
- Cortisol
- Central Nervous System
- Cognitive Function
- Healthy Ageing
- Small Fibre Neuropathy
- Cerebrospinal Fluid
- Electrocardiography

## Interventions

- **DRUG:** Xanamem
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT03830762
- **Lead sponsor:** Actinogen Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2019-12-07
- **Final completion:** 2020-01-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03830762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03830762, "Xanamem™ in Healthy Elderly Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03830762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*